1. Home
  2. VRAX

VRAX

Virax Biolabs Group Limited

Logo Virax Biolabs Group Limited

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

as 04-16-2024 2:32pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Founded: 2013 Country:
United Kingdom
United Kingdom
Employees: 11 City: N/A
Market Cap: 1.6M IPO Year: 2022
Target Price: N/A AVG Volume (30 days): 79.8K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.94 EPS Growth: N/A
52 Week Low/High: $0.70 - $8.54 Next Earning Date: 05-06-2024
Revenue: $79,301 Revenue Growth: -27.79%
Revenue Growth (this year): 16580.29% Revenue Growth (next year): 477.17%

Share on Social Networks: